Parents often ask me a simple question: "Is myopia management safe for young children?" The short answer is yes.
Modern myopia-management treatments are generally very safe when prescribed appropriately and monitored carefully. But in my view, safety is not the most important question.
The more important question is: "Is my child likely to benefit?"
Too much of the discussion surrounding myopia management focuses on treatment options. Not enough focuses on understanding what the child's eyes are actually doing.
Myopia Management Is Not About the Eyeglass Prescription
When parents hear that their child's myopia has increased from -1.00 to -2.00 diopters, they naturally focus on the glasses prescription. As a pediatric ophthalmologist, I am more interested in something else: axial length.
Axial length is the front-to-back length of the eye. In most children with progressive myopia, the eye continues to elongate over time. As the eye becomes longer, the prescription typically becomes more nearsighted.
More importantly, excessive axial elongation is associated with the long-term risks we worry about in highly myopic eyes, including retinal detachment, myopic macular degeneration, glaucoma, and other potentially vision-threatening complications later in life.
The eyeglass prescription tells us where a child is today. Axial length helps us understand where the eye is heading.
Accurate Serial Measurements Are the Key
A single axial length measurement is useful. A series of accurate measurements over time is far more valuable.
In my practice, myopia management is not a product. It is not a pair of glasses. It is not a bottle of eye drops. It is a process of understanding how rapidly an individual child's eyes are growing and whether that growth is changing over time.
Objective serial measurements help answer critical questions:
- Is the eye elongating faster than expected?
- Is the rate of growth accelerating?
- Is treatment slowing myopia progression and axial length progression?
- Is the current management plan working?
Without reliable longitudinal data, much of myopia management becomes educated guesswork. Families deserve better than guesswork.
Most Modern Myopia Treatments Have Excellent Safety Profiles
Several treatments have been shown to slow myopia progression and axial length progression in appropriately selected children, including:
- Low-dose atropine eye drops
- Myopia-control spectacle lenses
- Multifocal soft contact lenses
- Orthokeratology (ortho-k)
All of these approaches have demonstrated the ability to reduce myopia progression and axial elongation in at least some children.
None eliminates myopia. None completely stops eye growth. Additionally, nothing replaces the need for ongoing monitoring.
In general, the safety profile of modern myopia management is excellent. Serious complications are uncommon, particularly when children are followed appropriately and families understand their role in treatment.
Orthokeratology: Effective, But With Higher Risk
Orthokeratology deserves separate discussion because it is frequently marketed as a premium or superior treatment. The reality is more nuanced.
Orthokeratology uses rigid lenses worn overnight to temporarily reshape the cornea. It can reduce dependence on glasses and has been shown to slow myopia progression and axial elongation in many children.
However, current evidence does not demonstrate that orthokeratology is clearly superior to other contemporary myopia-management approaches.
What makes ortho-k different is not superior efficacy. It is a different risk profile.
Because the lenses are worn overnight, orthokeratology carries a higher risk of microbial keratitis and other contact-lens-related complications than atropine therapy, myopia-control spectacle lenses, or daytime contact lens.
To put this in perspective, the absolute risk remains relatively low. Orthokeratology is not an unsafe treatment.
However, among the commonly used myopia-management options, it generally carries the highest risk of a serious complication. That additional risk may still be acceptable for the right patient and family.
It is simply important to understand that ortho-k is not a risk-free shortcut and should not be viewed as categorically superior to other evidence-based treatments.
Not All Childhood Myopia Is the Same
One of the biggest misconceptions in pediatric eye care is that all childhood myopia represents the same disease. It does not.
A typical 8-year-old whose myopia begins in elementary school is often very different from a child who develops high myopia during infancy, toddlerhood, or the preschool years. These children frequently follow entirely different biological pathways.
Very Early High Myopia Often Has a Strong Genetic Basis
When I see a young child with very high myopia, one of my first questions is not how to treat it. My first question is: Why is it there?
Many cases of very early-onset high myopia have a strong genetic basis. Some are associated with monogenic forms of myopia or other inherited conditions that differ substantially from the more common progressive myopia seen in school-age children.
Others may result from conditions such as childhood glaucoma, where increased pressure inside the eye can cause the eye to literally expand, producing substantial myopia through an entirely different mechanism.
These children behave differently clinically. Parents are frequently surprised to learn that a child with extremely high myopia may show relatively little ongoing axial elongation over time.
The prescription may be large. The eye may not be continuing to elongate significantly.
This distinction is critical.
If minimal axial elongation is occurring, traditional myopia-management strategies may offer limited benefit because the primary problem is not ongoing excessive eye growth. Instead, the child may have developed a highly myopic eye as a consequence of an underlying genetic condition or other ocular disorder.
This is one reason I am cautious about applying standardized treatment algorithms to every child with a large prescription. Understanding the biology matters.
The Goal Is Not to Treat Every Myopic Child
The goal of myopia management should never be to place every nearsighted child into a treatment program. The goal is to identify children who are truly progressing, determine their level of risk, and intervene when evidence suggests that intervention is likely to help.
That requires:
- Accurate diagnosis
- Careful refraction
- Reliable axial length measurements
- Longitudinal follow-up
- Thoughtful interpretation of the data
Most importantly, it requires recognizing that not all myopia behaves the same way.
In Conclusion
Modern myopia-management treatments are generally very safe for children.
The real challenge is not determining whether treatment is safe. The real challenge is determining which children are likely to benefit.
In my practice, that process begins with accurate measurement and careful follow-up. While the eyeglass prescription remains important, axial length often provides the most meaningful information about future risk, myopia progression/axial length progression, and treatment response.
Orthokeratology can be a useful treatment option for selected patients, but current evidence does not establish that it is superior to other modern approaches. Because it involves overnight contact lens wear, it carries a higher complication risk than atropine therapy, myopia-control glasses, or most daytime optical treatments.
Most importantly, not all childhood myopia is the same. Children with very early-onset high myopia often have a strong genetic basis for their condition, frequently demonstrate relatively little axial length progression over time, and may derive limited benefit from conventional myopia-management interventions.
The best myopia-management strategy is not a product. It is understanding the individual child, measuring what matters, and making decisions based on objective evidence rather than assumptions.
Dr. Eric Lichtenstein provides pediatric ophthalmology and myopia-management care based on careful measurement, individualized assessment, and ongoing monitoring.
Contact The Pediatric Eye Center to schedule a consultation.
